GlassScriptPhysician profile
Kevin D'Rummo
NPI 1437512746
$3,014.55
in general payments reported to CMS, 2019-2025
41 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $542 · 2023: $802 · 2024: $880 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $305.92 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $260.72 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $231.43 | 2022-2025 | Rybrevant, Imbruvica, Darzalex |
| Lilly USA, LLC | $212.06 | 2022-2024 | Retevmo, Verzenio, Jaypirca |
| Incyte Corporation | $184.48 | 2022-2025 | Monjuvi, Pemazyre, Jakafi |
| Regeneron Healthcare Solutions, INC. | $127.15 | 2022-2025 | Libtayo, Lynozyfic |
| Pfizer INC. | $122.55 | 2024-2025 | |
| Abbvie INC. | $119.44 | 2022-2025 | |
| Genentech USA, INC. | $111.73 | 2023-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Aveo Pharmaceuticals, INC. | $86.38 | 2022-2025 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.65 | 2022-2025 | Gilotrif |
| Genzyme Corporation | $81.99 | 2022-2025 | |
| Seagen INC. | $80.89 | 2022-2023 | Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $73.97 | 2023-2025 | |
| Eisai INC. | $62.27 | 2022-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin D'Rummo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.